Jan 20 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback